To evaluate the efficacy, safety, and tolerability of LB-102 compared to placebo in adults with acute schizophrenia.
Approach:
Trial Design: NOVA1 was a double-blind, placebo-controlled, randomized clinical trial conducted at 25 inpatient sites in the US.
Participant Criteria: Eligible participants were adults aged 18-55 with a primary diagnosis of schizophrenia, requiring hospitalization for acute exacerbation of psychotic symptoms.
Randomization: Participants were randomized in a 3:3:3:1 ratio to receive LB-102 (50 mg, 75 mg, or 100 mg) or placebo.
Trial Duration: The trial lasted approximately 8 weeks, including an inpatient treatment period and a follow-up.
Key Findings:
LB-102 demonstrated sustained D2/D3 receptor blockade with lower systemic exposure compared to amisulpride.
Once-daily dosing of LB-102 achieved therapeutic receptor occupancy levels with reduced adverse effects.
The trial adhered to Good Clinical Practice and ethical standards.
Interpretation:
LB-102 may offer a favorable safety and efficacy profile for treating acute schizophrenia, addressing limitations of traditional antipsychotics.
Limitations:
The study's sample size for the 100 mg arm was smaller.
The trial was conducted in a specific inpatient setting, which may limit generalizability.
Conclusion:
LB-102 shows promise as a treatment option for acute schizophrenia, warranting further investigation in late-stage trials.
by Anna Eramo, Christoph U. Correll, David P. Walling, Rishi Kakar, Niccolo Bassani, Leslie Callahan, Baker P. Lee, Zachary Prensky, Andrew R. Vaino, John M. Kane
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
